Navigation Links
Isis Pharmaceuticals to Present at the 2009 Canaccord Adams Cardiovascular Conference
Date:11/3/2009

CARLSBAD, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Canaccord Adams' 2009 Cardiovascular Conference on Tuesday, November 10, 2009, at 11:00 a.m. PT at the Nikko Hotel in San Francisco.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
2. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
3. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
4. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
5. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
6. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
7. Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
8. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
9. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
10. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., a ... drug prescribing process, today announced it closed $25 million in ... venture capital firm based in Seattle ... Venture Partners . The Series B round included participation from ... in 2014, and GV (formerly Google Ventures). As ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive ... offering. ... market was valued at US$ 7,167.6 Mn in 2015, and ... at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... Getting enough sleep affects much more than energy – it also has mental and physical ... compromise motor reaction time, which can increase the risk of having a car accident. ... from the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce its ... has been in place since the RBMA was founded in 1968 with all board ... Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for Clinical ...
(Date:4/28/2017)... ... April 28, 2017 , ... From April ... of Urgent Care Medicine will host industry leaders for the annual spring Convention ... those in the industry adapt to the issues currently affecting urgent care and ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... which name the Creator responds to and which He does not. Yisrayl says with ... which one is the true name, but he says with a little Scripture, backed with ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a ... its Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, ... power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and ...
Breaking Medicine News(10 mins):